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Abstract
Objective: To evaluate the safety and efficacy of cryoablation for metastatic lung tumors from colorectal cancer.
Methods: The procedures were performed on 24 patients (36–82 years of age, with a median age of 62; 17 male patients, 7
female patients) for 55 metastatic tumors in the lung, during 30 sessions. The procedural safety, local progression free
interval, and overall survival were assessed by follow-up computed tomographic scanning performed every 3–4 months.
Results: The major complications were pneumothorax, 19 sessions (63%), pleural effusion, 21 sessions (70%), transient and
self-limiting hemoptysis, 13 sessions (43%) and tract seeding, 1 session (3%). The 1- and 3-year local progression free
intervals were 90.8% and 59%, respectively. The 3-years local progression free intervals of tumors #15 mm in diameter was
79.8% and that of tumors .15 mm was 28.6% (p=0.001; log-rank test). The 1- and 3-year overall survival rates were 91%
and 59.6%, respectively.
Conclusion: The results indicated that percutaneous cryoablation is a feasible treatment option. The local progression free
interval was satisfactory at least for tumors that were #15 mm in diameter.
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Introduction
Pulmonary metastases are common in patients with colorectal
cancer. The 5-year probability of survival was found to be 27–40%
[1,2,3,4,5,6,7] in patients who had undergone surgical resection.
In 1965, Thomford et al., reported criteria for resection of
metastatic lung tumors which have been generally accepted by the
surgical community [8]. Resectability depends on the number and
location of lesions, patient’s age, comorbidities and pulmonary
function tests as well as the ECOG performance status.
Nonsurgical candidates are usually managed with systemic
chemotherapy. As for chemotherapy, newer systemic chemother-
apeutic regimens for metastatic colorectal cancer have recently
shown improved response rates (35–50%) and overall survival (18–
20months) [9,10,11]. Still, a less invasive local therapeutic option
is desirable, that is as effective as surgery.
Many interventional radiologists regard cryoablation as an
intraoperative modality used by urologists and general surgeons
for prostate gland [12] and liver tumor ablations [13], respectively.
Although percutaneous cryoablation of the thorax has also been
reported in 2005 [14], percutaneous cryoablation is still not as
widely applied as radiofrequency ablation for lung tumors [15].
During the cryoablation, the cryoprobe uses high-pressure argon
and helium gases for freezing and thawing, respectively, on the
basis of the Joule-Thompson principle. The ice ball can be
detected by CT as ground glass opacity. The air in the lung can
interfere with the creation of the ice ball. When the cryoprobe is
inserted into normal pulmonary parenchyma, initial freezing
causes the formation of an ice ball with a diameter of only 1 cm
because the air prevents conduction of low temperatures, and
there is not enough water in the parenchyma. However, after
thawing, the massive intra-alveolar hemorrhage excludes the air
and results in the formation of a larger ice ball in the subsequent
freezing step. We therefore performed 3 freeze/thaw cycles to
freeze a volume of tissue 2.5–3.0 cm in diameter.
We have previously reported the preliminary results of
percutaneous cryoablation for lung tumors performed under
computed tomography (CT) guidance with local anesthesia as a
local curative treatment, which showed promising perioperative
outcomes and local disease control in a mixed group of tumors
[16]. However, the survival benefits of cryoablation remain
unclear, and the type of patients that would benefit from this
procedure is also unknown. In order to evaluate the safety and
efficacy of this procedure for pulmonary metastasis from colorectal
cancer, we have retrospectively reviewed the safety, the local
progression free interval, and the survival rates in 24 nonsurgical
candidates in this study. To our knowledge, this is the first report
of the feasibility as well as the local control potential of
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colorectal cancer, which is one of the most frequently encountered
metastatic lesions in the lung.
Methods
Ethics
This study protocol was approved by Keio University
institutional review board (approval ID: 14–23). Written informed
consent was obtained from each participant in accordance with
the Declaration of Helsinki.
Patient Selection
This was a retrospective study of patients treated for metastatic
pulmonary tumors from colorectal cancer in our institution from
November 2002 through May 2007. Patients with more than 3
years of follow-up were reviewed.
A patient was deemed non surgical due to any of the following:
(1) multiple previous thoracotomies (2) multifocal disease (3)
concomitant tumors (4) patient refused surgery, (5) respiratory
dysfunction, or (6) advanced age. The threshold of respiratory
dysfunction was below 800 mL with predicted post-operative
forced expiratory volume in one second. Written informed consent
was obtained from all patients. The exclusion criteria were as
follows: (1) The ECOG performance status was 2 or 3. (2) The
platelet count was less than 50,000/mL. (3) The prothrombin time
international normalized ratio was more than 1.5. (4) The largest
tumor diameter was greater than 40 mm as measured by
preoperative volumetric CT. (5) There was no suitable way for
the insertion of probes due to interference by major vasculatures,
airways or mediastinal structures. (6) The primary colorectal
carcinoma had not been controlled. (7) The patient was deemed
incapable of cooperating during the procedure.
When the patient had metastases in bilateral lungs, we
performed the treatment sequentially on different days.
Cryoablation Technique
All the cryoablation procedures were performed using a
multidetector CT scanner (Aquilion 64; Toshiba Med. Co. Ltd.,
Tokyo, Japan), which enables use of multislice CT fluoroscopy.
Before leaving the ward, each patient received an intramuscular
injection of atropine sulfate (0.5 mg) and pentazocine (15 mg),
used for the premedication to ally patients’ anxiety and reduce the
bowel movement during the procedure. Cryoablation was
performed after administration of local anesthesia by a thoracic
surgeon or by a radiologist. A twenty-one-gauge guide needle was
inserted into the targeted tumor under CT-fluoroscopic guidance.
The needle always penetrated the tumor and the tip of the needle
was placed at the far end of the lesion. With the needle in optimal
position, a coaxial stainless steel introducer for the cryoprobe was
inserted over the needle. The introducer consisted of inner tapered
obturator and external sheath. The inner and outer diameters of
the external sheath for a 1.7-mm-diameter cryoprobe (CRYOcare
Cryosurgical Unit; Endocare, Irvine, CA) were 2 and 3 mm,
respectively. The area of the heat exchanger segment is 4 cm from
the tip of both types of the probes. After the guiding needle and
inner sheath were removed, a cryoprobe was inserted through the
external sheath. The sheath was 180 mm long, equal to the length
of the cryoprobe, and therefore the cryoprobe tip was located at
the end of the sheath. Cryoablation procedure consisted of 3
freezing cycles (one cycle of 5 minutes and 2 cycles of 10 minutes)
separated by 3 thawing cycles during which the probe was allowed
to reach a temperature of 20uC. There is a thermocouples device
built into the cryoprobe. The probe temperature was monitored
real-time automatically. The 1.7 mm-diameter cryoprobes can
freeze a volume of tissue with a diameter of 2 cm [17,18], and
measuring 4 cm in length, after 3 cycles of freezing and thawing.
Therefore, for tumors smaller than 2 cm, only 1 cryoprobe is
usually inserted, and for 2- to 3-cm tumors, 2 or more cryoprobes
are used to freeze a more-than-3-mm thick rind of normal tissue
around the tumor. It takes 20–30 min to place a guide needle into
the optimal position in the targeted tumor, and cryoablation starts
simultaneously after all cryoprobes are placed. Once cryoablation
is completed, fibrin glue (BolhealH, The Chemo-Sero-Therapeutic
Research Institute, Kumamoto, Japan) is injected through the
sheath to reduce the risk of bleeding and pneumothorax. One ml
of fibrinogen and 1 ml of thrombin per one probe were injected
into the sheath simultaneously.
Evaluation and Statistical Analysis
Complications were recorded and classified in accordance with
the Common Terminology Criteria of Adverse Events (CTCAE)
v4.0. We also evaluated radiographic local tumor control and
overall survival. Radiographic local tumor control was assessed by
criteria published in 2005 [19]. A post-operative plain thoracic CT
was performed immediately after the removal of the cryoprobes
for verification of any major complications such as air embolism,
hemothorax, or tension pneumothorax, had occurred. CT scans
were also performed at both 1 day and 1 week after the
cryoablation procedure. Follow-up dynamic CT chest scans of
patients were carried out at 1-month and then at 3- to 4-month
intervals. Unenhanced chest CT was performed in patients with
iodine allergies. The modified RECIST criteria [20] were basically
used to assess response. CT scans in every case are reviewed by
three diagnostic radiologists (M.I., H.Y. and S.N.) with 13, 14 and
20 years of clinical experiences, respectively, to determine whether
progression had occurred. Diagnoses were made independently,
and these radiologists discussed when they turned out to be
different. In some cases, consolidation with ground grass opacity
located adjacent to the treated lesion makes it difficult to detect the
tumor progression. In such cases, a CT-guided needle biopsy was
also performed to obtain a definitive diagnosis. Kaplan-Meier with
log-rank analysis was used to analyze local progression free
interval and cumulative survival after the initial cryoablation. All
statistical analyses were performed using SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA). Statistical significance was set at
p,0.05.
Results
Clinical Data
Percutanous cryoablation was performed on 24 patients (36–82
years of age, median age: 62 years; 17 male patients, 7 female
patients) for 55 metastatic lung tumors from colorectal cancer in
30 sessions. Most of the patients had undergone treatment for lung
metastases before cryoablation: 17 patients had received chemo-
therapy, 14 patients had undergone lung surgery, and 2 patients
had undergone stereotactic radiosurgery. Therapeutic option of
cryoablation was chosen according to the criteria stated earlier.
Three patients refused surgery; twenty-one patients were nonsur-
gical candidates due to multiple tumors or insufficient pulmonary
function (Table 1). The cryoablation procedures were well-
tolerated by all patients under local anesthesia. Two patients
required an additional injection of pentazocine (15 mg) during the
procedure. The mean procedure time was 136637 min (range,
66–192 min).
The mean tumor diameter was 1367 mm (range, 3–31 mm).
Of the 55 lesions, 34 lesions were treated by using 1 cryoprobe; 19
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(Table 2). Three tumors were too hard to be transfixed by the
probe. For these tumors, two probes were placed adjacent to the
tumors.
Perioperative Outcomes
Pneumothorax occurred in 19 sessions (63%) with 16 patients
(66%), mostly immediately after the completion of the ablation
procedure. The insertion of a chest tube was required in 1 session
(3%) in one patient (4%). A small amount of pleural effusion
occurred in 21 sessions (70%) in 17 patients (71%), but none of the
patients required the insertion of a chest tube to control the
effusion. Transient hemoptysis occurred after cryoablation in 13
sessions (43%) in 10 patients (42%), and during cryoablation in 3
sessions (10%) in 3 patients (12.5%). No interventions were
required in any of these patients. In all cases, perioperative pain
was controlled by loxoprofen, which was stopped within 1 week.
Some patients in our study complained of dull pain in the anterior
chest soon after treatment, which was probably due to intercostal
nerves’ damage. However, their pain usually resolved within a few
months. There were neither treatment-related deaths nor
conversions to surgical intervention. A tract seeding was observed
in 1 case, 5 months after cryoablation. The tumor was controlled
by surgical resection of the chest muscles and skin.
Local progression free interval and overall survival
The median follow-up period was 40 months. Up to the date of
the last follow-up of each patient, 17 tumors (26%) showed disease
progression at the original cryoablation site, and hence median
local progression free interval could not be determined. Local
progression free interval at 1- and 3-years after treatment was
90.8% and 59%, respectively (Figure 1).
Local progression free interval was significantly greater for
lesions with a diameter less than 15 mm. The 3-years local
progression free interval of tumors #15 mm in diameter was
79.8% and that of tumors .15 mm in diameter was 28.6%
(p=0.001, log-rank test) (Figure 2).
Median overall survival was 43 months (8–86). One- and 3-year
overall survival rates of 91% and 59.6%, respectively. (Figure 3).
We also analyzed Local progression free interval, and overall
survival according to age, and treatments before cryoablation. We
compared the patients aged ,63 versus .=63, since 63 was the
Table 1. Patient characteristics.
Number of patients
Sex
Male 17
Female 7
Age (yr)
Average 62.0
Range 36–82
Number of lesions treated
11 1
27
3 or more 6
Past history of other metastasis
Lung 14
Liver 5
Brain 1
Prostate 1
Reasons for cryoablation
Refusal of surgery 3
Unresectability 21
Multiple metastases 12
Insufficient pulmonary function 12
Old age 1
Treatment for pulmonary metastasis before cryoablation
Chemotherapy 17
Surgery 14
Single surgery 7
More than 2 surgeries 7
Radiation 2
doi:10.1371/journal.pone.0027086.t001
Table 2. Characteristics of tumors.
Number of tumors
Tumor diameter (mm)
Average 13
Range 3–31
Local control
Local recurrence 10
No recurrence 45
Number of cryoprobes per tumors
13 4
21 9
.32
doi:10.1371/journal.pone.0027086.t002
Figure 1. Local progression free interval curve. The median
follow-up period was 40 months. Up to the date of the last follow-up of
each patient, 17 tumors (26%) showed disease progression at the
original cryoablation site, and hence median local progression free
interval could not be determined. Local progression free interval at 1-
and 3-years after treatment was 90.8% and 59%, respectively.
doi:10.1371/journal.pone.0027086.g001
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two groups by the age ,63 (n=29) versus .=63 (n=26), the
progression free interval of the two groups has no significant
difference by log-lank test (p=0.77). Also, the survival of the two
groups, ,63 (n=12) versus .=63 (n=12) did not differ
significantly by log-lank test (p=0.1). As for the treatment before
cryoablation, when we divided the tumors into two groups with or
without chemotherapy before cryoablation (n=48 and n=7,
respectively), the local progression free interval of the two group
did not differ significantly by log-lank test (p=0.545). The overall
survival of two groups (n=17 and n=7, respectively) also did not
differ significantly by log-lank test (p=0.568).When we divided the
tumors in two groups with or without surgery before cryoablation
(n=27 and n=28, respectively), the local progression free interval
of the two group did not differ significantly by log-lank test
(p=0.220). The overall survival of two groups (n=14 and n=10,
respectively) also did not differ significantly by log-lank test
(p=0.583). When we divided the tumors in two groups with or
without radiosurgery before cryoablation (n=5 and n=50,
respectively), the local progression free interval of the two group
did not differ significantly by log-lank test (p=0.158). The overall
survival of two groups (n=2 and n=22, respectively) also did not
differ significantly by log-lank test (p=0.586).
Discussion
Cryoablation has been performed for hepatic and for prostate
cancer, and it has shown acceptable results; however, in most cases
it was performed under general or epidural anesthesia. In our
clinical study, all the procedures were performed under local
anesthesia, which is similar to the conditions in the study by Wang
et al. [14]. We therefore retrospectively evaluated the feasibility as
well as the local control potential of cryoablation for lung
metastasis from colorectal cancer.
With regard to the complications associated with cryoablation,
the frequency of pneumothorax observed in our study was higher
than the frequency of pneumothorax reported in a study by Wang
et al [14]. In our study, we performed chest CT in all the cases one
day after the procedure to check for the existence of pneumotho-
rax. This may be why we found substantial number of
asymptomatic pneumothorax. The results of our study were
comparable with a report of percutaneous radiofrequency ablation
by Yamagami T et al. [21], in which Grade 2 pneumothorax
occurred in 19 of 129 sessions (14.7%), and the insertion of a chest
tube was required in 5 sessions (3.9%).
There were some reports about radiofrequency ablation for
lung metastases from colorectal cancer [22,23]. In these reports, 1-
and 3-year overall survival was 84–96%, 48–56%, respectively and
1- and 3-year progression free survival was 72–90%, 56–79%,
respectively. These percentages in these studies were similar to our
result.
There are several possible reasons for the local progression free
interval difference depending on the tumor size: (1) The existence
of a physical limitation in the ablation size when only 1 cryoprobe
is used. Our experiments in pigs have shown that a cryoablation
probe can freeze an area (known as an ‘‘ice ball’’) of about 2 cm in
diameter [17,18]. (2) We still have little information on the size
and shape of the ablation area when several probes are used
simultaneously, although some experimental reports in vivo showed
the thermal map of 2 probes [24] and the effect of freeze time [25].
(3) Patients with larger metastatic lung lesions have a greater
probability of other metastatic disease including micro-metastases
or satellite lesions [3,26]. Improvement in local progression free
interval, most probably by increasing the number of cryoprobes
per tumor, will be necessary for future treatments.
One of the potential advantages of cryoablation is that
cryoablation preserves the collagenous architecture and prevents
the perforation and/or destruction of the cartilaginous rings of the
bronchial tree [27]. Limited data are available about the effects on
larger airways of cryoablation and of thermoablation. But case
reports in the literature give the impression that radiofrequency
ablation is more likely to result in larger air leaks that may progress
to bronchopleural fistulae [28]. Moorjani et al reported that
cryoanalgesia of 250uC for 1 minute on the intercostal nerves did
not damage the neural structures. This allowed regrowth of the
nerve through the perineurial canal [29]. This may be why
intercostal nerves’ pain in most patients in our study was
Figure 2. Local progression free interval curve according to
tumor diameter. Local progression free interval was significantly
greater for lesions with a diameter less than 15 mm. The 3-years local
progression free interval of tumors #15 mm in diameter was 79.8% and
that of tumors .15 mm in diameter was 28.6% (p=0.001, log-rank
test).
doi:10.1371/journal.pone.0027086.g002
Figure 3. The overall survival curve after first cryoablation.
Median overall survival was 43 months (8–86). One- and 3-year overall
survival rates of 91% and 59.6%, respectively.
doi:10.1371/journal.pone.0027086.g003
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irreversible pain. These features also suggest its superiority over
heat-based ablation of lung tumors, especially near large vessels,
the tracheobronchial region, or other mediastinal structures,
though it has been reported to cause ‘‘cryoshock phenomenon’’
in hepatic cryoablation [30,31,32] and to cause renal parenchymal
fracture in renal cryoablation [33].
The present study represents an early experience, with a small
number of patients Hence extrapolation of the results to clinical
practice should be performed with caution. Further confounding
effects of the therapies received before cryoablation cannot be
ruled out. Besides, the main limitation of this report is the lack of
long-term follow-up data. Therefore, this was not a definitive study
either for assessing the effects of cryoablation on patient survival,
the effectiveness of cryoablation in the treatment of newly
diagnosed lung metastasis from colon cancer, or for determining
whether cryoablation was as effective as surgery for lung tumors.
In conclusion, percutaneous cryoablation may have a useful role
in the management of colorectal pulmonary metastases less than
15 mm in diameter, when surgical resection is not an option. To
realize the potential of this therapeutic modality for larger lesions,
further research will be needed on the kinetics of heat transfer
during freezing of pulmonary tumours.
Author Contributions
Conceived and designed the experiments: YY MK SN HN. Performed the
experiments: YY SN YI HY NT KA MI. Analyzed the data: YY SN YI.
Contributed reagents/materials/analysis tools: SN HY NT KA MI. Wrote
the paper: YY MK YI HN.
References
1. McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, et al. (1992)
Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 53:
780–785; discussion 785–786.
2. McCormack PM, Burt ME, Bains MS, Martini N, Rusch VW, et al. (1992) Lung
resection for colorectal metastases. 10-year results. Arch Surg 127: 1403–1406.
3. Shirouzu K, Isomoto H, Hayashi A, Nagamatsu Y, Kakegawa T (1995) Surgical
treatment for patients with pulmonary metastases after resection of primary
colorectal carcinoma. Cancer 76: 393–398.
4. Girard P, Ducreux M, Baldeyrou P, Rougier P, Le Chevalier T, et al. (1996)
Surgery for lung metastases from colorectal cancer: analysis of prognostic factors.
J Clin Oncol 14: 2047–2053.
5. Okumura S, Kondo H, Tsuboi M, Nakayama H, Asamura H, et al. (1996)
Pulmonary resection for metastatic colorectal cancer: experiences with 159
patients. J Thorac Cardiovasc Surg 112: 867–874.
6. Regnard JF, Grunenwald D, Spaggiari L, Girard P, Elias D, et al. (1998)
Surgical treatment of hepatic and pulmonary metastases from colorectal cancers.
Ann Thorac Surg 66: 214–218; discussion 218–219.
7. Rena O, Casadio C, Viano F, Cristofori R, Ruffini E, et al. (2002) Pulmonary
resection for metastases from colorectal cancer: factors influencing prognosis.
Twenty-year experience. Eur J Cardiothorac Surg 21: 906–912.
8. Thomford NR, Woolner LB, Clagett OT (1965) The Surgical Treatment of
Metastatic Tumors in the Lungs. J Thorac Cardiovasc Surg 49: 357–363.
9. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, et al. (2004) FOLFIRI
followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a
randomized GERCOR study. J Clin Oncol 22: 229–237.
10. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, et al. (2005) Phase III
randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced
colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia
Meridionale. J Clin Oncol 23: 4866–4875.
11. Kelly H, Goldberg RM (2005) Systemic therapy for metastatic colorectal cancer:
current options, current evidence. J Clin Oncol 23: 4553–4560.
12. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, et al. (2002) Targeted
cryoablation of the prostate: 7-year outcomes in the primary treatment of
prostate cancer. Urology 60: 3–11.
13. Lee FT, Jr., Mahvi DM, Chosy SG, Onik GM, Wong WS, et al. (1997) Hepatic
cryosurgery with intraoperative US guidance. Radiology 202: 624–632.
14. Wang H, Littrup PJ, Duan Y, Zhang Y, Feng H, et al. (2005) Thoracic masses
treated with percutaneous cryotherapy: initial experience with more than 200
procedures. Radiology 235: 289–298.
15. Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, et al.
(2000) Percutaneous radiofrequency ablation of malignancies in the lung. AJR
Am J Roentgenol 174: 57–59.
16. Kawamura M, Izumi Y, Tsukada N, Asakura K, Sugiura H, et al. (2006)
Percutaneous cryoablation of small pulmonary malignant tumors under
computed tomographic guidance with local anesthesia for nonsurgical
candidates. J Thorac Cardiovasc Surg 131: 1007–1013.
17. Nakatsuka S, Yashiro H, Inoue M, Kuribayashi S, Kawamura M, et al. (2010)
On freeze-thaw sequence of vital organ of assuming the cryoablation for
malignant lung tumors by using cryoprobe as heat source. Cryobiology 61:
317–326.
18. Izumi Y, Oyama T, Ikeda E, Kawamura M, Kobayashi K (2005) The acute
effects of transthoracic cryoablation on normal lung evaluated in a porcine
model. Ann Thorac Surg 79: 318–322; discussion 322.
19. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD, 3rd, et al.
(2005) Image-guided tumor ablation: standardization of terminology and
reporting criteria. J Vasc Interv Radiol 16: 765–778.
20. Fernando HC, De Hoyos A, Landreneau RJ, Gilbert S, Gooding WE, et al.
(2005) Radiofrequency ablation for the treatment of non-small cell lung cancer
in marginal surgical candidates. J Thorac Cardiovasc Surg 129: 639–644.
21. Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, et al. (2006)
Pneumothorax as a complication of percutaneous radiofrequency ablation for
lung neoplasms. J Vasc Interv Radiol 17: 1625–1629.
22. Hiraki T, Gobara H, Iishi T, Sano Y, Iguchi T, et al. (2007) Percutaneous
radiofrequency ablation for pulmonary metastases from colorectal cancer:
midterm results in 27 patients. J Vasc Interv Radiol 18: 1264–1269.
23. Yamakado K, Inoue Y, Takao M, Takaki H, Nakatsuka A, et al. (2009) Long-
term results of radiofrequency ablation in colorectal lung metastases: single
center experience. Oncol Rep 22: 885–891.
24. Permpongkosol S, Nicol TL, Khurana H, Link RE, Zhai QJ, et al. (2007)
Thermal maps around two adjacent cryoprobes creating overlapping ablations
in porcine liver, lung, and kidney. J Vasc Interv Radiol 18: 283–287.
25. Auge BK, Santa-Cruz RW, Polascik TJ (2006) Effect of freeze time during renal
cryoablation: a swine model. J Endourol 20: 1101–1105.
26. Shiono S, Ishii G, Nagai K, Yoshida J, Nishimura M, et al. (2005) Predictive
factors for local recurrence of resected colorectal lung metastases. Ann Thorac
Surg 80: 1040–1045.
27. Deygas N, Froudarakis M, Ozenne G, Vergnon JM (2001) Cryotherapy in early
superficial bronchogenic carcinoma. Chest 120: 26–31.
28. Sakurai J, Hiraki T, Mukai T, Mimura H, Yasui K, et al. (2007) Intractable
pneumothorax due to bronchopleural fistula after radiofrequency ablation of
lung tumors. J Vasc Interv Radiol 18: 141–145.
29. Moorjani N, Zhao F, Tian Y, Liang C, Kaluba J, et al. (2001) Effects of
cryoanalgesia on post-thoracotomy pain and on the structure of intercostal
nerves: a human prospective randomized trial and a histological study.
Eur J Cardiothorac Surg 20: 502–507.
30. Seifert JK, Stewart GJ, Hewitt PM, Bolton EJ, Junginger T, et al. (1999)
Interleukin-6 and tumor necrosis factor-alpha levels following hepatic cryother-
apy: association with volume and duration of freezing. World J Surg 23:
1019–1026.
31. Chapman WC, Debelak JP, Blackwell TS, Gainer KA, Christman JW, et al.
(2000) Hepatic cryoablation-induced acute lung injury: pulmonary hemody-
namic and permeability effects in a sheep model. Arch Surg 135: 667–672;
discussion 672–663.
32. Washington K, Debelak JP, Gobbell C, Sztipanovits DR, Shyr Y, et al. (2001)
Hepatic cryoablation-induced acute lung injury: histopathologic findings. J Surg
Res 95: 1–7.
33. Hruby G, Edelstein A, Karpf J, Durak E, Phillips C, et al. (2008) Risk factors
associated with renal parenchymal fracture during laparoscopic cryoablation.
BJU Int 102: 723–726.
Cryoablation of Lung Metastases from Colon Cancer
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27086